Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALOMA: CPX-351 vs Conventional Care Before AlloHCT in Higher Risk MDS and Oligoblastic AML
NCT04061239Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- Aug 2019
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of daunorubicin + cytarabine liposome in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (2 arms), sponsored by GWT-TUD. Primary endpoint: Event-Free Survival at 2 years. Started Aug 2019; status: completed.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04061239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061239.